Study of CB307 in Patients With Advanced and/or Metastatic PSMA-positive Tumours.

Phase 1 Unknown 70 enrolled Crescendo Biologics Ltd.

Non-randomizedSingle-groupOpen-labelTreatment

Summary

FIH, Phase 1, open-label, multi centre study of CB307, a trispecific Humabody® T-cell enhancer, in patients with advanced and/or metastatic PSMA+ solid tumours to assess safety and tolerability to determine MTD and preliminary RP2D.In addition this study will assess the safety and efficacy of CB307 when given in combination with pembrolizumab (KEYTRUDA®) in patients with metastatic PSMA+ castration-resistant cancer

Timeline

Start: 2021-06-08
Primary completion: 2024-07-25
Completion: 2024-09-25

Publications

Wilford T, Bartlett PD, Schlag A, Jasaitis L, Pandha H, Pierce AJ, Hughes R. Solving selectivity issues in LBAs: case study using Gyrolab to quantify CB307, a bispecific Humabody in human serum. Bioanalysis. 2024;16(14):757-769. doi: 10.1080/17576180.2024.2365545. Epub 2024 Jul 3.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CB307	Other / unclassified	—	Intravenous

Indications

No indication recorded.